Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for ...
© 2026 Forbes Media LLC. All Rights Reserved.
Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - ...
CytomX Therapeutics Inc (CTMX) reports encouraging results from its Varseta-M study, with plans for a pivotal trial and expansion into new tumor types.
Bank of America has raised its Brent oil price forecast for 2026 as disruptions in the Strait of Hormuz tighten global supply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results